General Medicine Raises $120M to Scale Healthcare Store

The moment after a patient understands what care might help is where healthcare turns back into work. The answer still has to survive insurance rules, cash pricing, medical records, clinical review, scheduling, referrals and a physical system organized around providers rather than the person trying to get better.

General Medicine has raised a $120M Series B to make that handoff easier. Andreessen Horowitz led the financing, with Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup participating. The October 6, 2026 round brings the San Francisco company's total disclosed funding to $152M.

The capital will help General Medicine expand a nationwide healthcare store that lets customers search, compare and buy care, see insurance and cash prices before deciding, or ask a licensed clinician for guidance. Its catalog now spans more than 2,900 products and services across medications, labs, telehealth, specialist e-consults and select in-person visits and procedures.

What General Medicine Raised and Who Backed It

The $120M Series B was led by Andreessen Horowitz, where General Partner Vineeta Agarwala, MD, PhD, led the investment. Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup joined the round. General Medicine had disclosed $32M in earlier backing when it launched nationwide in May 2025, but the company has not disclosed a valuation for the Series B.

The investor set reaches beyond venture firms. Eli Lilly participates from the medicine side of the market, while Mercy Health sits inside physical care delivery. Their presence does not establish a commercial partnership beyond the financing, but it does put capital from institutions close to the fulfillment system General Medicine is trying to make easier for consumers to navigate.

Why the Healthcare Store Is More Than a Marketplace

Healthcare services are difficult to shop because the same service can be described differently by a patient, clinician, insurer, laboratory or health system. General Medicine's core infrastructure is a common product catalog that reconciles those definitions so an option can be priced, compared, matched and fulfilled through one storefront.

Customers can enter in 3 ways. They can buy care directly when they know what they need, talk with a licensed clinician for guidance, or use an AI chat interface to explore symptoms and possible next steps. Health history and context can follow the customer across those paths, and licensed clinicians retain responsibility for clinical decisions when review is required.

That distinction matters because AI is making health information and preliminary guidance easier to obtain. The a16z investment thesis argues that the harder problem begins after the advice, when a person must find the right service, understand its price, gather records and carry the process into the physical world. General Medicine is financing that execution layer.

The Founders Reorganized Before Scaling

The financing arrives with a founder-led leadership transition. TJ Parker joined General Medicine full time as CEO in October 2026 after serving as a co-founder, board member and early investor while working as a General Partner at Matrix. Ashwin Muralidharan, the founding CEO, moved into the Chief Product Officer role and continues to lead product, engineering, design, clinical, operations and much of the business day to day. Elliot Cohen remains President.

Parker and Cohen previously co-founded PillPack, the online pharmacy Amazon acquired in 2018, and helped build Amazon Pharmacy and Amazon Clinic. Muralidharan joined Amazon Pharmacy in 2019 to work on pricing and marketplace experiences. Their current bet carries a familiar operating lesson: a consumer experience can look simple only after somebody has absorbed the complexity underneath it.

What the Early Traction Says

General Medicine reports hundreds of thousands of customer signups nationwide and an average Net Promoter Score of 80 since launch. The company says 83% of customers addressed a health need they had postponed, including one-third who had delayed care for more than 6 months. It also says the average customer record spans 11 years when presented to clinicians as a prioritized summary.

Those figures are company-reported rather than independently audited. They still indicate which problem General Medicine is trying to measure: the distance between wanting care and completing the next useful action. Fierce Healthcare reported that the company is expanding gradually from standardized services such as pharmacy and lab testing toward imaging and a wider range of outpatient procedures.

What the $120M Changes

General Medicine says the Series B will expand the store into more categories of care. That means more services to define, more prices to explain, more provider relationships to coordinate and more clinical pathways where the software must hand the work to a person without losing the customer's context.

The company's current hiring page reflects that breadth, with roles across clinical care, engineering, product, revenue-cycle management, recruiting and strategic finance. General Medicine is scaling a technology product, a medical operation and a transaction layer at the same time. Each new category makes the storefront more useful while increasing the coordination burden behind it.

The Larger Digital Health Signal

Digital health has spent years narrowing care into condition-specific apps, virtual clinics and point solutions. General Medicine is moving in the opposite direction by building a broader catalog that can connect digital guidance to medications, labs, specialists and selected in-person services.

The ambition is larger than making telehealth easier to buy. General Medicine wants the customer to become the organizing unit of the market, with providers, payers, drugmakers and care platforms competing inside a clearer purchasing experience. The Series B gives Parker, Muralidharan and Cohen room to expand that system while preserving clinical independence and making the machinery behind each transaction less visible to the person trying to use it.